



# COVID-19 VACCINES DOSSIER

## ADVERSE REACTIONS DATA

Extract from **EudraVigilance** report updated on February, 27, 2021

by **Gospa News** ©

[www.gospanews.net](http://www.gospanews.net) ITA/ENG versions

## PREMESSA ALLA LETTURA DEI DATI EUDRAVIGILANCE SULLE REAZIONI AVVERSE AI VACCINI

*Le informazioni contenute in questo sito riguardano i sospetti effetti indesiderati, ovvero eventi clinici osservati in seguito all'uso di un medicinale, che tuttavia non sono necessariamente correlati o provocati dal medicinale. Le informazioni concernenti i sospetti effetti indesiderati non devono essere interpretate nel senso che il medicinale o il principio attivo sono effettivamente causa dell'effetto osservato o che il loro uso non è sicuro. Solo una valutazione dettagliata e un esame scientifico approfonditi di tutti i dati disponibili consentono di trarre conclusioni fondate sui benefici e sui rischi di un medicinale.*

*L'Agenzia europea per i medicinali pubblica questi dati in modo tale che le parti interessate, compreso il pubblico in generale, abbiano accesso alle informazioni utilizzate dalle autorità europee di regolamentazione per riesaminare la sicurezza di un medicinale o di un principio attivo. La trasparenza è un principio guida fondamentale dell'Agenzia. Ogni singolo caso registrato in EudraVigilance si riferisce in generale a un paziente; tuttavia, una segnalazione può contenere riferimenti a più di un effetto indesiderato. Pertanto, il numero di effetti indesiderati non corrisponderà necessariamente al numero dei casi singoli.*

Sono le premesse scritte dall'Agenzia Europea del Farmaco (European Medicines Agency – EMA) nella presentazione dei dati di farmacovigilanza raccolti da EudraVigilance ed elaborati dal sistema Oracle ([http://www.adrreports.eu/it/search\\_subst.html#](http://www.adrreports.eu/it/search_subst.html#))

La vastità e complessità dei dati relativi ai molteplici disturbi segnalati tra le reazioni avverse al vaccino ci hanno costretti ad elaborare un estratto sintetico che è pertanto parziale ed incompleto. Ci siamo limitati a riassumere i dati inerenti agli esiti fatali (morti), quelli sui vaccinati con disturbi non ancora guariti-risolti (NOT RECOVERED) nelle tabelle) e quelli ancora in stato di ricovero (RECOVERING) perchè rappresentano ancora due categorie a rischio. Per brevità abbiamo riportato il numero totale dei casi in relazione ad ognuno dei tre vaccini già approvati con autorizzazione sperimentale di emergenza dall'Agenzia Europea del Farmaco (Pfizer-Biontech, Moderna e Astrazeneca) ed ai principali gruppi di disturbi come suddivisi dalla stessa EudraVigilance.

Nelle tabelle riepilogative da noi stilate abbiamo omissi i numerosi casi delle persone già guarite dalle reazioni avverse, quelle guarite ma con conseguenze ed infine le statistiche relative alle situazioni "sconosciute". Infatti, come è possibile vedere nei grafici EudraVigilance relativi alle segnalazioni delle più gravi reazioni avverse (gastrointestinali, infezioni, disturbi nervosi e respiratori) che abbiamo allegato, c'è un alto numero di cui risulta sconosciuto l'esito, legittimando il dubbio che le conseguenze fatali o non risolte possano essere molte di più di quelle riportate finora. A ciò si aggiungono le inquietanti voci inserite tra i gruppi di patologie denominate "disturbi generali" e "investigazioni" che riuniscono casi di reazioni avverse non completamente identificate sebbene anche mortali.

Ciò rende evidente che questa Farmacovigilanza è soltanto la prima "spia" di un'analisi scientifica che richiederebbe un imponente approfondimento di ricerca (esami di cartelle cliniche, autopsie ecc) probabilmente destinato a restare solo un'ipotesi dinnanzi l'emergenza pandemica ancora in essere. L'ultima nota di rilievo è che 138 persone sono morte proprio di Covid-19 nonostante i vaccini, e altri 298 sono ancora a rischio in quanto affetti dall'infezione da virus SARS-Cov-2.

## INTRODUCTION TO THE READING OF EUDRAVIGILANCE DATA ON ADVERSE REACTIONS TO VACCINES

*The information contained on this site concerns suspected side effects, or clinical events observed following the use of a medicine, which, however, are not necessarily related to or caused by the medicine. Information concerning suspected side effects should not be interpreted as meaning that the medicine or active ingredient actually causes the observed effect or that their use is unsafe. Only a detailed evaluation and thorough scientific examination of all available data allow you to draw well-founded conclusions about the benefits and risks of a medicine.*

*The European Medicines Agency publishes this data so that interested parties, including the general public, have access to information used by European regulatory authorities to review the safety of a medicine or active substance. Transparency is a fundamental guiding principle of the Agency. Each single case registered in EudraVigilance generally refers to a patient; however, a report may contain references to more than one side effect. Therefore, the number of side effects will not necessarily match the number of individual cases.*

These are the premises written by the European Medicines Agency (EMA) in the presentation of pharmacovigilance data collected by EudraVigilance and processed by the Oracle system ([http://www.adrreports.eu/it/search\\_subst.html#](http://www.adrreports.eu/it/search_subst.html#))

The vastness and complexity of the data relating to the many disorders reported among the adverse reactions to the vaccine have forced us to develop a synthetic extract which is therefore partial and incomplete. We have limited ourselves to summarizing the data relating to fatal outcomes (deaths), those on vaccinated people with disorders not yet cured-resolved and those still in hospital because they still represent two risk categories.

For the sake of brevity, we have reported the total number of cases in relation to each of the three vaccines already approved with experimental emergency authorization from the European Medicines Agency (Pfizer-Biontech, Moderna and Astrazeneca) and the main groups of disorders as subdivided by EudraVigilance itself.

In the summary tables we compiled we have omitted the numerous cases of people already healed from adverse reactions, those healed but with sequelae (consequences) and finally the statistics relating to "unknown" situations. In fact, as you can see in the EudraVigilance graphs relating to the reports of the most serious adverse reactions (gastrointestinal, infections, nervous and respiratory disorders) that we have attached, there is a high number of which the outcome is unknown, legitimizing the doubt that fatal or unresolved consequences may be many more than those reported so far. Added to this are the disturbing items inserted between the groups of pathologies called "general disorders" and "investigations" which bring together cases of adverse reactions that are not completely identified although also fatal.

This makes it clear that this Pharmacovigilance is only the first "spy" of a scientific analysis that would require an impressive in-depth research (medical records, autopsies, etc.) probably destined to remain only a hypothesis in front of the pandemic emergency still in place. The last important note is that 138 people have died of Covid-19 despite vaccines, and another 298 are still at risk as they are infected with the SARS-Cov-2 virus.



Reaction Groups\Seriousness	Number of individual cases			Total
	Non Serious	Not Specified	Serious	
Blood and lymphatic system disorders	4,428	0	1,330	5,758
Cardiac disorders	1,394	0	2,108	3,502
Congenital, familial and genetic disorders	1	0	13	14
Ear and labyrinth disorders	1,286	0	775	2,061
Endocrine disorders	10	0	27	37
Eye disorders	1,135	0	1,131	2,266
Gastrointestinal disorders	11,364	0	6,176	17,540
General disorders and administration site conditions	40,483	0	14,334	54,817
Hepatobiliary disorders	11	0	58	69
Immune system disorders	356	0	1,207	1,563
Infections and infestations	1,545	0	3,072	4,617
Injury, poisoning and procedural complications	709	0	1,033	1,742
Investigations	1,440	0	1,858	3,298
Metabolism and nutrition disorders	430	0	733	1,163
Musculoskeletal and connective tissue disorders	21,289	0	6,741	28,030
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	4	0	32	36
Nervous system disorders	23,064	0	10,997	34,061
Pregnancy, puerperium and perinatal conditions	3	0	43	46
Product issues	35	0	11	46
Psychiatric disorders	1,413	0	1,435	2,848
Renal and urinary disorders	109	0	261	370
Reproductive system and breast disorders	215	0	183	398
Respiratory, thoracic and mediastinal disorders	2,967	0	3,985	6,952
Skin and subcutaneous tissue disorders	5,099	0	3,571	8,670
Social circumstances	31	0	125	156
Surgical and medical procedures	31	0	26	57
Vascular disorders	1,734	0	1,883	3,617
<b>Total</b>	<b>55,223</b>	<b>0</b>	<b>23,082</b>	<b>78,305</b>



# moderna

Reaction Groups\Seriousness	Number of individual cases			Total
	Non Serious	Not Specified	Serious	
Blood and lymphatic system disorders	110	0	67	177
Cardiac disorders	25	0	215	240
Congenital, familial and genetic disorders	0	0	1	1
Ear and labyrinth disorders	22	0	44	66
Endocrine disorders	0	0	2	2
Eye disorders	21	0	82	103
Gastrointestinal disorders	338	0	401	739
General disorders and administration site conditions	1,402	0	929	2,331
Hepatobiliary disorders	0	0	8	8
Immune system disorders	8	0	140	148
Infections and infestations	45	0	237	282
Injury, poisoning and procedural complications	28	0	87	115
Investigations	47	0	202	249
Metabolism and nutrition disorders	14	0	78	92
Musculoskeletal and connective tissue disorders	655	0	326	981
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0	0	5	5
Nervous system disorders	585	0	725	1,310
Pregnancy, puerperium and perinatal conditions	0	0	6	6
Product issues	0	0	3	3
Psychiatric disorders	22	0	123	145
Renal and urinary disorders	1	0	37	38
Reproductive system and breast disorders	12	0	11	23
Respiratory, thoracic and mediastinal disorders	76	0	369	445
Skin and subcutaneous tissue disorders	167	0	240	407
Social circumstances	1	0	26	27
Surgical and medical procedures	0	0	23	23
Vascular disorders	31	0	164	195
<b>Total</b>	<b>1,645</b>	<b>0</b>	<b>1,621</b>	<b>3,266</b>

# AstraZeneca



Reaction Groups\Seriousness	Number of individual cases			Total
	Non Serious	Not Specified	Serious	
Blood and lymphatic system disorders	30	0	199	229
Cardiac disorders	80	0	443	523
Congenital, familial and genetic disorders	0	0	4	4
Ear and labyrinth disorders	49	0	234	283
Endocrine disorders	0	0	15	15
Eye disorders	49	0	407	456
Gastrointestinal disorders	623	0	3,637	4,260
General disorders and administration site conditions	2,824	0	8,146	10,970
Hepatobiliary disorders	0	0	6	6
Immune system disorders	2	0	190	192
Infections and infestations	39	0	753	792
Injury, poisoning and procedural complications	8	0	171	179
Investigations	76	0	504	580
Metabolism and nutrition disorders	59	0	562	621
Musculoskeletal and connective tissue disorders	1,428	0	3,861	5,289
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0	0	4	4
Nervous system disorders	1,618	0	6,588	8,206
Pregnancy, puerperium and perinatal conditions	0	0	9	9
Product issues	0	0	3	3
Psychiatric disorders	51	0	663	714
Renal and urinary disorders	12	0	131	143
Reproductive system and breast disorders	1	0	44	45
Respiratory, thoracic and mediastinal disorders	97	0	875	972
Skin and subcutaneous tissue disorders	174	0	1,378	1,552
Social circumstances	5	0	26	31
Surgical and medical procedures	0	0	30	30
Vascular disorders	45	0	348	393
<b>Total</b>	<b>3,053</b>	<b>0</b>	<b>10,930</b>	<b>13,983</b>


BIONTECH



The number of individual cases identified in EudraVigilance for **TOZINAMERAN** is **78,305** (up to 27/02/2021)


#### Number of individual cases by Age Group

Age Group	Cases	%
Not Specified	4,179	5.3%
0-1 Month	33	0.0%
2 Months - 2 Years	41	0.1%
3-11 Years	46	0.1%
12-17 Years	43	0.1%
18-64 Years	63,897	81.6%
65-85 Years	6,531	8.3%
More than 85 Years	3,535	4.5%
<b>Total</b>	<b>78,305</b>	<b>100.0%</b>




#### Number of individual cases by Sex

Sex	Cases	%
Female	60,647	77.4%
Male	16,367	20.9%
Not Specified	1,291	1.6%
<b>Total</b>	<b>78,305</b>	<b>100.0%</b>



#### Number of individual cases by Geographic Origin (EEA/Non-EEA)




Occurrence Country EEA/Non EEA	Cases	%
European Economic Area	65,136	83.2%
Non European Economic Area	13,169	16.8%
Not Specified	0	
<b>Total</b>	<b>78,305</b>	<b>100.0%</b>






Number of individual cases identified in EudraVigilance in EEA countries for **TOZINAMERAN** (up to 27/02/2021)

1 to 3 for that country






Choose how you want to see the number of individual cases identified in EudraVigilance for **TOZINAMERAN** (up to 27/02/2021)



Choose how you want to see the number of individual cases identified in EudraVigilance for **TOZINAMERAN** (up to 27/02/2021)



REACTION GROUPS	FATAL	NOT RECOVERED	RECOVERING	TOTAL
<input type="checkbox"/> Blood and lymphatic system disorders	13	1,540	1,600	5,758
<input type="checkbox"/> Cardiac disorders	211	443	567	3,502
<input type="checkbox"/> Congenital, familial and genetic disorders	1	4	1	14
<input type="checkbox"/> Ear and labyrinth disorders	0	467	439	2,061
<input type="checkbox"/> Endocrine disorders	0	11	6	37
<input type="checkbox"/> Eye disorders	2	502	486	2,335
<input type="checkbox"/> Gastrointestinal disorders	101	2,628	3,696	17,540
<input type="checkbox"/> General disorders and administration site conditions	758	8,570	11,714	54,817
<input type="checkbox"/> Hepatobiliary disorders	8	13	14	69
<input type="checkbox"/> Immune system disorders	9	149	268	1,574
<input type="checkbox"/> Infections and infestations	201 (101 Covid)	1,035 (265 Covid)	846	4,697
<input type="checkbox"/> Injury, poisoning and procedural complications	21	183	196	1,756
<input type="checkbox"/> Investigations	82	513	566	3,362
<input type="checkbox"/> Metabolism and nutrition disorders	39	232	215	1,169
<input type="checkbox"/> Musculoskeletal and connective tissue disorders	13	4,772	6,059	28,989
<input type="checkbox"/> Neoplasms benign, malignant and unspecified (incl cysts and polyps)	2	11	4	36
<input type="checkbox"/> Nervous system disorders	132	5,661	6,854	35,282
<input type="checkbox"/> Pregnancy, puerperium and perinatal conditions	2	4	14	46
<input type="checkbox"/> Product issues	0	2	2	46
<input type="checkbox"/> Psychiatric disorders	26	422	441	2,921
<input type="checkbox"/> Renal and urinary disorders	29	70	61	374
<input type="checkbox"/> Reproductive system and breast disorders	0	122	71	417
<input type="checkbox"/> Respiratory, thoracic and mediastinal disorders	223	1,298	94	7,243
<input type="checkbox"/> Skin and subcutaneous tissue disorders	13	1,643	1,870	9,001
<input type="checkbox"/> Social circumstances	6	41	14	157
<input type="checkbox"/> Surgical and medical procedures	3	7	11	214
<input type="checkbox"/> Vascular disorders	57	480	624	3,659
<b>ADVERSE REACTIONS AFTER PFIZER VACCINES</b>	<b>2,012</b>	<b>29,823</b>	<b>36,733</b>	<b>187,075</b>

### Reaction Groups & Reported Suspected Reaction




#### Reaction Groups

Gastrointestinal disorders

#### Reported Suspected Reaction

Abdominal adhesions  
Abdominal discomfort  
Abdominal distension  
Abdominal pain  
Abdominal pain lower  
Abdominal pain upper  
Abdominal rigidity  
Abdominal symptom  
Abdominal tenderness  
Abdominal wall haematoma  
Abdominal wall haemorrhage  
Abnormal faeces  
Acetonaemic vomiting  
Acquired macroglossia  
Acute abdomen  
Aerophagia  
Anaesthesia oral  
Anal fissure  
Anal fistula  
Anal haemorrhage  
Anal incontinence  
Anal pruritus  
Anal sphincter atony  
Angular cheilitis  
Anorectal discomfort  
Aphthous ulcer  
Aptyalism  
Ascites  
Bowel movement irregularity  
Breath odour  
Burning mouth syndrome  
Change of bowel habit  
Chapped lips  
Cheilitis  
Colitis  
Colitis microscopic  
Colitis ulcerative  
Constipation  
Crohn's disease  
Defaecation urgency  
Dental discomfort  
Dental paraesthesia  
Diarrhoea  
Diarrhoea haemorrhagic  
Discoloured vomit  
Diverticulum intestinal

### Number of individual cases by Age Group & Sex, Reporter Group and Outcome





Choose a Reaction Group and then a Reported Suspected Reaction to see the number of individual cases identified in EudraVigilance for **TOZINAMERAN** (up to 27/02/2021)

### Reaction Groups & Reported Suspected Reaction




#### Reaction Groups

Infections and infestations

#### Reported Suspected Reaction

Abdominal infection  
Abscess  
Abscess oral  
Acarodermatitis  
Acne pustular  
Adenoiditis  
Adenoviral conjunctivitis  
Administration site abscess  
African trypanosomiasis  
Appendicitis  
Arthritis bacterial  
Asymptomatic COVID-19  
Atypical pneumonia  
Bacteraemia  
Bacterial diarrhoea  
Bacterial infection  
Beta haemolytic streptococcal infection  
Biliary sepsis  
Blister infected  
Borrelia infection  
Breast abscess  
Bronchitis  
Bronchitis bacterial  
Bronchopulmonary aspergillosis  
Bursitis infective  
COVID-19  
COVID-19 pneumonia  
Candida infection  
Cellulitis  
Cholecystitis infective  
Chorioretinitis  
Clostridium difficile colitis  
Clostridium difficile infection  
Coccidioidomycosis  
Complicated appendicitis  
Conjunctivitis  
Conjunctivitis bacterial  
Conjunctivitis viral  
Coronavirus infection  
Creutzfeldt-Jakob disease  
Cystitis  
Cytomegalovirus infection  
Dacryocystitis  
Dermo-hypodermatitis  
Disseminated Bacillus Calmette-Guerin infection  
Disseminated varicella zoster virus infection

### Number of individual cases by Age Group & Sex, Reporter Group and Outcome



Choose a Reaction Group and then a Reported Suspected Reaction to see the number of individual cases identified in EudraVigilance for **TOZINAMERAN** (up to 27/02/2021)

### Reaction Groups & Reported Suspected Reaction




#### Reaction Groups

Nervous system disorders

#### Reported Suspected Reaction

Acoustic neuritis  
Acute disseminated encephalomyelitis  
Acute polyneuropathy  
Ageusia  
Akathisia  
Allodynia  
Altered state of consciousness  
Amnesia  
Anaesthesia  
Anosmia  
Anterograde amnesia  
Anticholinergic syndrome  
Aphasia  
Areflexia  
Ataxia  
Aura  
Autoimmune demyelinating disease  
Autonomic nervous system imbalance  
Axonal neuropathy  
Balance disorder  
Band sensation  
Basal ganglia haemorrhage  
Basal ganglia stroke  
Basilar artery thrombosis  
Brachial plexopathy  
Bradykinesia  
Brain compression  
Brain injury  
Brain oedema  
Brain stem haemorrhage  
Brain stem infarction  
Brain stem stroke  
Brain stem syndrome  
Burning feet syndrome  
Burning sensation  
Burning sensation mucosal  
Carotid artery dissection  
Carpal tunnel syndrome  
Central nervous system lesion  
Central pain syndrome  
Cerebellar ataxia  
Cerebellar haemorrhage  
Cerebellar infarction  
Cerebellar stroke  
Cerebellar syndrome  
Cerebral disorder

### Number of individual cases by Age Group & Sex, Reporter Group and Outcome



Choose a Reaction Group and then a Reported Suspected Reaction to see the number of individual cases identified in EudraVigilance for **TOZINAMERAN** (up to 27/02/2021)

### Reaction Groups & Reported Suspected Reaction




#### Reaction Groups

Respiratory, thoracic and mediastinal disorders

#### Reported Suspected Reaction

Acute pulmonary oedema  
Acute respiratory distress syndrome  
Acute respiratory failure  
Allergic cough  
Allergic respiratory symptom  
Allergic sinusitis  
Aphonia  
Apnoea  
Apnoeic attack  
Asphyxia  
Aspiration  
Asthma  
Asthma exercise induced  
Asthmatic crisis  
Atelectasis  
Bronchial disorder  
Bronchial hyperreactivity  
Bronchial oedema  
Bronchial wall thickening  
Bronchiectasis  
Bronchitis chronic  
Bronchopneumopathy  
Bronchospasm  
Bronchostenosis  
Catarrh  
Cheyne-Stokes respiration  
Choking  
Choking sensation  
Chronic obstructive pulmonary disease  
Cough  
Diaphragmalgia  
Diaphragmatic paralysis  
Diaphragmatic spasm  
Dry throat  
Dysaesthesia pharynx  
Dysphonia  
Dyspnoea  
Dyspnoea at rest  
Dyspnoea exertional  
Emphysema  
Epiglottic oedema  
Epistaxis  
Grunting  
Haemoptysis  
Hiccups  
Hypercapnia

### Number of individual cases by Age Group & Sex, Reporter Group and Outcome





# moderna

---






The number of individual cases identified in EudraVigilance for **COVID-19 MRNA VACCINE MODERNA (CX-024414)** is **3,266** (up to 27/02/2021)


Number of individual cases by Age Group

Age Group	Cases	%
Not Specified	215	6.6%
0-1 Month	0	
2 Months - 2 Years	0	
3-11 Years	0	
12-17 Years	1	0.0%
18-64 Years	2,161	66.2%
65-85 Years	633	19.4%
More than 85 Years	256	7.8%
<b>Total</b>	<b>3,266</b>	<b>100.0%</b>




Number of individual cases by Sex

Sex	Cases	%
Female	2,357	72.2%
Male	881	27.0%
Not Specified	28	0.9%
<b>Total</b>	<b>3,266</b>	<b>100.0%</b>






Number of individual cases by Geographic Origin (EEA/Non-EEA)

Occurrence Country EEA/Non EEA	Cases	%
European Economic Area	1,914	58.6%
Non European Economic Area	1,352	41.4%
Not Specified	0	
<b>Total</b>	<b>3,266</b>	<b>100.0%</b>




Number of individual cases identified in EudraVigilance in EEA countries for **COVID-19 MRNA VACCINE MODERNA (CX-024414)** (up to 27/02/2021)

less or equal to 3 for that country




Choose how you want to see the number of individual cases identified in EudraVigilance for **COVID-19 MRNA VACCINE MODERNA (CX-024414)** (up to 27/02/2021)

Reaction Groups



Choose how you want to see the number of individual cases identified in EudraVigilance for **COVID-19 MRNA VACCINE MODERNA (CX-024414)** (up to 27/02/2021)

Reaction Groups





REACTION GROUPS	FATAL	NOT RECOVERED	RECOVERING	TOTAL
<input type="checkbox"/> Blood and lymphatic system disorders	2	55	51	177
<input type="checkbox"/> Cardiac disorders	42	44	15	240
<input type="checkbox"/> Congenital, familial and genetic disorders	0	0	0	0
<input type="checkbox"/> Ear and labyrinth disorders	0	18	16	52
<input type="checkbox"/> Endocrine disorders	0	1	0	2
<input type="checkbox"/> Eye disorders	1	35	11	103
<input type="checkbox"/> Gastrointestinal disorders	17	130	120	730
<input type="checkbox"/> General disorders and administration site conditions	201	462	548	2,331
<input type="checkbox"/> Hepatobiliary disorders	0	3	0	8
<input type="checkbox"/> Immune system disorders	1	23	6	148
<input type="checkbox"/> Infections and infestations	32 (22 Covid)	68 (17 Covid)	34	282
<input type="checkbox"/> Injury, poisoning and procedural complications	11	22	4	115
<input type="checkbox"/> Investigations	24	55	20	249
<input type="checkbox"/> Metabolism and nutrition disorders	13	23	10	92
<input type="checkbox"/> Musculoskeletal and connective tissue disorders	13	209	238	981
<input type="checkbox"/> Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1	3	0	5
<input type="checkbox"/> Nervous system disorders	64	238	224	1,310
<input type="checkbox"/> Pregnancy, puerperium and perinatal conditions	0	2	0	6
<input type="checkbox"/> Product issues	0	0	0	3
<input type="checkbox"/> Psychiatric disorders	10	30	11	145
<input type="checkbox"/> Renal and urinary disorders	4	12	2	38
<input type="checkbox"/> Reproductive system and breast disorders	0	2	5	23
<input type="checkbox"/> Respiratory, thoracic and mediastinal disorders	46	100	35	445
<input type="checkbox"/> Skin and subcutaneous tissue disorders	8	97	73	407
<input type="checkbox"/> Social circumstances	1	19	2	27
<input type="checkbox"/> Surgical and medical procedures	4	9	0	23
<input type="checkbox"/> Vascular disorders	14	37	19	195
<b>ADVERSE REACTIONS AFTER MODERNA VACCINE</b>	<b>533</b>	<b>1,697</b>	<b>1,444</b>	<b>8,137</b>

Choose a Reaction Group and then a Reported Suspected Reaction to see the number of individual cases identified in EudraVigilance for **COVID-19 MRNA VACCINE MODERNA (CX-024414)** (up to 27/02/2021)

### Reaction Groups & Reported Suspected Reaction




#### Reaction Groups

Gastrointestinal disorders

#### Reported Suspected Reaction

Abdominal adhesions  
Abdominal discomfort  
Abdominal distension  
Abdominal pain  
Abdominal pain lower  
Abdominal pain upper  
Abdominal rigidity  
Acute abdomen  
Anal incontinence  
Anal sphincter atony  
Ascites  
Bowel movement irregularity  
Cheilitis  
Colitis  
Colitis ischaemic  
Constipation  
Cyclic vomiting syndrome  
Defaecation urgency  
Diarrhoea  
Diarrhoea haemorrhagic  
Diverticulum intestinal  
Dry mouth  
Dyspepsia  
Dysphagia  
Enlarged uvula  
Eructation  
Faecaloma  
Faeces discoloured  
Faeces pale  
Flatulence  
Frequent bowel movements  
Gastric dilatation  
Gastric haemorrhage  
Gastrointestinal disorder  
Gastrointestinal haemorrhage  
Gastrointestinal hypermotility  
Gastrointestinal oedema  
Gastrointestinal pain  
Gastrointestinal sounds abnormal  
Gastrooesophageal reflux disease  
Gingival pain  
Glossitis  
Glossodynia  
Haematemesis  
Haematochezia  
Haemoperitoneum

### Number of individual cases by Age Group & Sex, Reporter Group and Outcome



Reaction Groups & Reported Suspected Reaction




Reaction Groups

Infections and infestations

Reported Suspected Reaction

- Abscess neck
- Appendicitis
- Arthritis bacterial
- Asymptomatic COVID-19
- Atypical pneumonia
- Bacterial infection
- Bronchitis
- COVID-19
- COVID-19 pneumonia
- Candida infection
- Cellulitis
- Cholecystitis infective
- Complicated appendicitis
- Conjunctivitis
- Cystitis
- Dermo-hypodermatitis
- Diverticulitis
- Dysentery
- Ear infection
- Encephalitis
- Encephalitis viral
- Endocarditis
- Erysipelas
- Erythema migrans
- Escherichia bacteraemia
- Eye infection
- Gastroenteritis viral
- Herpes ophthalmic
- Herpes simplex
- Herpes simplex reactivation
- Herpes zoster
- Infection
- Infectious mononucleosis
- Influenza
- Injection site abscess
- Injection site cellulitis
- Injection site infection
- Kidney infection
- Lymphangitis
- Mastitis
- Meningitis
- Meningitis aseptic
- Meningitis viral
- Nasopharyngitis
- Ophthalmic herpes simplex
- Ophthalmic herpes zoster

Number of individual cases by Age Group & Sex, Reporter Group and Outcome





## Reaction Groups & Reported Suspected Reaction




### Reaction Groups

Nervous system disorders

### Reported Suspected Reaction

Brain stem infarction  
Burning sensation  
Burning sensation mucosal  
Carotid arteriosclerosis  
Central nervous system vasculitis  
Cerebellar stroke  
Cerebral artery embolism  
Cerebral artery occlusion  
Cerebral disorder  
Cerebral haemorrhage  
Cerebral infarction  
Cerebral microangiopathy  
Cerebral small vessel ischaemic disease  
Cerebral venous sinus thrombosis  
Cerebral ventricle dilatation  
Cerebrovascular accident  
Choreoathetosis  
Cognitive disorder  
Coma  
Consciousness fluctuating  
Coordination abnormal  
Dementia  
Depressed level of consciousness  
Diplegia  
Disturbance in attention  
Dizziness  
Dizziness postural  
Drooling  
Dysarthria  
Dysgeusia  
Dysgraphia  
Dyskinesia  
Dysstasia  
Dystonic tremor  
Embolic stroke  
Encephalopathy  
Epilepsy  
Facial paralysis  
Facial paresis  
Formication  
Generalised tonic-clonic seizure  
Guillain-Barre syndrome  
Haemorrhagic stroke  
Head discomfort  
Head titubation  
Headache

## Number of individual cases by Age Group & Sex, Reporter Group and Outcome





### Reaction Groups & Reported Suspected Reaction




#### Reaction Groups

Respiratory, thoracic and mediastinal disorders

#### Reported Suspected Reaction

Acute respiratory distress syndrome  
Acute respiratory failure  
Aphonia  
Asthma  
Atelectasis  
Bronchospasm  
Choking  
Choking sensation  
Chronic obstructive pulmonary disease  
Cough  
Dry throat  
Dysphonia  
Dyspnoea  
Dyspnoea exertional  
Epistaxis  
Grunting  
Haemoptysis  
Hiccups  
Hyperventilation  
Hypopnoea  
Hypoxia  
Interstitial lung disease  
Laryngeal oedema  
Larynx irritation  
Lower respiratory tract congestion  
Lung consolidation  
Lung disorder  
Lung hyperinflation  
Lung infiltration  
Lung opacity  
Mediastinal disorder  
Nasal congestion  
Nasal discomfort  
Nasal dryness  
Nasal septum deviation  
Obstructive airways disorder  
Organising pneumonia  
Oropharyngeal blistering  
Oropharyngeal discomfort  
Oropharyngeal oedema  
Oropharyngeal pain  
Oropharyngeal spasm  
Oropharyngeal swelling  
Painful respiration  
Paranasal cyst  
Pharyngeal hypoaesthesia

### Number of individual cases by Age Group & Sex, Reporter Group and Outcome




AstraZeneca



The number of individual cases identified in EudraVigilance for **COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)** is **13,983** (up to 27/02/2021)


Number of individual cases by Age Group

Age Group	Cases	%
Not Specified	596	4.3%
0-1 Month	15	0.1%
2 Months - 2 Years	42	0.3%
3-11 Years	73	0.5%
12-17 Years	12	0.1%
18-64 Years	9,463	67.7%
65-85 Years	3,490	25.0%
More than 85 Years	292	2.1%
Total	13,983	100.0%




Number of individual cases by Sex

Sex	Cases	%
Female	10,296	73.6%
Male	3,249	23.2%
Not Specified	438	3.1%
Total	13,983	100.0%



Number of individual cases by Geographic Origin (EEA/Non-EEA)




Occurrence Country EEA/Non EEA	Cases	%
European Economic Area	4,032	28.8%
Non European Economic Area	9,951	71.2%
Not Specified	0	
Total	13,983	100.0%






Number of individual cases identified in EudraVigilance in EEA countries for **COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)** (up to 27/02/2021)

Number of cases is less or equal to 3 for that country




Choose how you want to see the number of individual cases identified in EudraVigilance for **COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)** (up to 27/02/2021)



Choose how you want to see the number of individual cases identified in EudraVigilance for **COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)** (up to 27/02/2021)

Reaction Groups



REACTION GROUPS	FATAL	NOT RECOVERED	RECOVERING	TOTAL
<input type="checkbox"/> Blood and lymphatic system disorders	3	91	69	177
<input type="checkbox"/> Cardiac disorders	35	92	106	538
<input type="checkbox"/> Congenital, familial and genetic disorders	0	2	1	4
<input type="checkbox"/> Ear and labyrinth disorders	0	86	70	287
<input type="checkbox"/> Endocrine disorders	0	3	4	15
<input type="checkbox"/> Eye disorders	1	135	123	469
<input type="checkbox"/> Gastrointestinal disorders	10	1,002	1,028	4,660
<input type="checkbox"/> General disorders and administration site conditions	80	2,912	3,381	13,747
<input type="checkbox"/> Hepatobiliary disorders	0	1	3	7
<input type="checkbox"/> Immune system disorders	1	26	58	194
<input type="checkbox"/> Infections and infestations	36(15 Covid)	200(16 Covid)	232	812
<input type="checkbox"/> Injury, poisoning and procedural complications	2	26	35	179
<input type="checkbox"/> Investigations	2	130	123	595
<input type="checkbox"/> Metabolism and nutrition disorders	5	192	166	624
<input type="checkbox"/> Musculoskeletal and connective tissue disorders	1	1,613	1,554	5,603
<input type="checkbox"/> Neoplasms benign, malignant and unspecified (incl cysts and polyps)	2	0	0	4
<input type="checkbox"/> Nervous system disorders	27	2,085	2,097	9,230
<input type="checkbox"/> Pregnancy, puerperium and perinatal conditions	0	2	1	10
<input type="checkbox"/> Product issues	0	2	0	3
<input type="checkbox"/> Psychiatric disorders	2	142	139	744
<input type="checkbox"/> Renal and urinary disorders	3	49	2	148
<input type="checkbox"/> Reproductive system and breast disorders	0	15	11	46
<input type="checkbox"/> Respiratory, thoracic and mediastinal disorders	23	289	219	1,024
<input type="checkbox"/> Skin and subcutaneous tissue disorders	1	434	366	1,648
<input type="checkbox"/> Social circumstances	2	6	4	31
<input type="checkbox"/> Surgical and medical procedures	0	7	7	30
<input type="checkbox"/> Vascular disorders	6	86	70	397
<b>ADVERSE REACTIONS AFTER ASTRAZENECA VACCINE</b>	<b>242</b>	<b>9,628</b>	<b>9,869</b>	<b>41,226</b>



Choose a Reaction Group and then a Reported Suspected Reaction to see the number of individual cases identified in EudraVigilance for **COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)** (up to 27/02/2021)

### Reaction Groups & Reported Suspected Reaction




#### Reaction Groups

Gastrointestinal disorders

#### Reported Suspected Reaction

Abdominal discomfort  
Abdominal distension  
Abdominal mass  
Abdominal pain  
Abdominal pain lower  
Abdominal pain upper  
Abdominal rigidity  
Abdominal symptom  
Abnormal faeces  
Acute abdomen  
Anal incontinence  
Anorectal discomfort  
Aphthous ulcer  
Breath odour  
Burning mouth syndrome  
Change of bowel habit  
Chapped lips  
Cheilitis  
Colitis  
Colitis ischaemic  
Colitis ulcerative  
Constipation  
Crohn's disease  
Dental paraesthesia  
Diarrhoea  
Diarrhoea haemorrhagic  
Discoloured vomit  
Dry mouth  
Dyspepsia  
Dysphagia  
Eructation  
Faecaloma  
Faeces discoloured  
Flatulence  
Frequent bowel movements  
Functional gastrointestinal disorder  
Gastric dilatation  
Gastric haemorrhage  
Gastric ulcer  
Gastritis  
Gastrointestinal disorder  
Gastrointestinal haemorrhage  
Gastrointestinal motility disorder  
Gastrointestinal pain  
Gastrooesophageal reflux disease  
Gingival bleeding

### Number of individual cases by Age Group & Sex, Reporter Group and Outcome



Choose a Reaction Group and then a Reported Suspected Reaction to see the number of individual cases identified in EudraVigilance for **COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)** (up to 27/02/2021)

### Reaction Groups & Reported Suspected Reaction




#### Reaction Groups

Infections and infestations

#### Reported Suspected Reaction

AIDS related complex  
Abscess  
Arthritis bacterial  
Asymptomatic COVID-19  
Bacterial infection  
COVID-19  
COVID-19 pneumonia  
Cellulitis  
Conjunctivitis  
Cystitis  
Dysentery  
Ear infection  
Encephalitis  
Fungal infection  
Gastroenteritis  
Gastroenteritis viral  
Genital herpes  
Gingivitis  
H2N2 influenza  
Herpes zoster  
Infected lymphocele  
Infection  
Infectious mononucleosis  
Influenza  
Injection site infection  
Intervertebral discitis  
Kidney infection  
Labyrinthitis  
Laryngitis  
Localised infection  
Lower respiratory tract infection  
Mastitis  
Mumps  
Myelitis  
Nasopharyngitis  
Neutropenic sepsis  
Oral herpes  
Pharyngitis  
Pneumonia  
Post viral fatigue syndrome  
Pulmonary sepsis  
Q fever  
Rash pustular  
Rhinitis  
Roseola  
Secondary transmission

### Number of individual cases by Age Group & Sex, Reporter Group and Outcome



Choose a Reaction Group and then a Reported Suspected Reaction to see the number of individual cases identified in EudraVigilance for **COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)** (up to 27/02/2021)

### Reaction Groups & Reported Suspected Reaction




#### Reaction Groups

Nervous system disorders

#### Reported Suspected Reaction

Ageusia  
Akathisia  
Allodynia  
Amnesia  
Anosmia  
Aphasia  
Ataxia  
Autonomic nervous system imbalance  
Balance disorder  
Band sensation  
Bradykinesia  
Brain injury  
Brain oedema  
Brain stem infarction  
Brain stem stroke  
Burning feet syndrome  
Burning sensation  
Cerebral disorder  
Cerebral haemorrhage  
Cerebral infarction  
Cerebral thrombosis  
Cerebral venous sinus thrombosis  
Cerebral venous thrombosis  
Cerebrovascular accident  
Cerebrovascular disorder  
Clonic convulsion  
Clumsiness  
Cluster headache  
Cognitive disorder  
Coma  
Coordination abnormal  
Dementia  
Dementia Alzheimer's type  
Depressed level of consciousness  
Diplegia  
Disturbance in attention  
Dizziness  
Dizziness exertional  
Dizziness postural  
Drooling  
Dysaesthesia  
Dysarthria  
Dysgeusia  
Dyskinesia  
Dysstasia  
Dystonia

### Number of individual cases by Age Group & Sex, Reporter Group and Outcome





Choose a Reaction Group and then a Reported Suspected Reaction to see the number of individual cases identified in EudraVigilance for **COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)** (up to 27/02/2021)

### Reaction Groups & Reported Suspected Reaction




#### Reaction Groups

Respiratory, thoracic and mediastinal disorders

#### Reported Suspected Reaction

Acute pulmonary oedema  
Aphonia  
Aspiration  
Asthma  
Asthmatic crisis  
Bronchospasm  
Catarrh  
Choking  
Choking sensation  
Chronic obstructive pulmonary disease  
Cough  
Dry throat  
Dysphonia  
Dyspnoea  
Dyspnoea exertional  
Epistaxis  
Haemoptysis  
Hiccups  
Hyperventilation  
Hypopnoea  
Hypoxia  
Lung disorder  
Mouth breathing  
Nasal congestion  
Nasal discomfort  
Nasal dryness  
Nasal obstruction  
Nasal pruritus  
Oropharyngeal discomfort  
Oropharyngeal pain  
Oropharyngeal swelling  
Orthopnoea  
Pharyngeal erythema  
Pharyngeal hypoaesthesia  
Pharyngeal oedema  
Pharyngeal paraesthesia  
Pharyngeal swelling  
Pleurisy  
Pneumonia aspiration  
Pneumonitis  
Pneumothorax  
Productive cough  
Pulmonary congestion  
Pulmonary embolism  
Pulmonary haemorrhage  
Pulmonary infarction

### Number of individual cases by Age Group & Sex, Reporter Group and Outcome







Come abbiamo evidenziato in molteplici **reportages del ciclo WuhanGates**, il fondatore di Microsoft Corporation e ideatore del piano di Immunizzazione mondiale, **Bill Gates, controlla direttamente o indirettamente le più grandi Big Pharma dei vaccini anti-Covid-19**. Attraverso GlaxoSmithKline, infatti, controlla Pfizer (in percentuali variabili fino al 68 % come in Italia), che ha sviluppato il vaccino Comirnaty con BioNTech in cui ha investito lo stesso Gates. Sanofi, multinazionale che stava sviluppando il vaccino con GSK si è già accordata per produrre quello di Pfizer. Inoltre anche Moderna ha ricevuto investimenti finanziari dalla Fondazione Bill & Melinda Gates.

Il piano COVAX interno all'Organizzazione mondiale della Sanità, gestito da un'ex manager GSK per conto delle ONG Gavi Alliance e Cepi fondate dallo stesso Gates, ha già fatto accordi per l'acquisto di vaccini delle multinazionali nell'orbita dello stesso Gates da donare a popolazioni povere grazie a contributi di varie nazioni in un palese conflitto d'interessi tra speculatore e benefattore. Non va dimenticato che la fondazione del guru IT ha per più di dieci anni finanziato i pericolosi esperimenti batteriologici nell'Istituto di Wuhan dove sono stati progettati i supervirus SARS infettati con HIV, come alcuni esperti ritengono essere il SARS-Cov-2.

*I dettagli nel libro WuhanGates e nella voce del menu Gospa News così denominata.*

As we have highlighted in multiple **reports of the WuhanGates cycle**, the founder of Microsoft Corporation and creator of the global immunization plan, **Bill Gates, directly or indirectly controls the largest Big Pharma of anti-Covid-19 vaccines**. Through GlaxoSmithKline, in fact, he controls Pfizer (in variable percentages up to 68% as in Italy), which developed the Comirnaty vaccine with BioNTech in which Gates himself has invested. Sanofi, a multinational that was developing the vaccine with GSK, has already agreed to produce Pfizer's. In addition, Moderna also received financial investments from the Bill & Melinda Gates Foundation.

The COVAX plan within the World Health Organization, managed by a former GSK manager on behalf of the NGOs Gavi Alliance and Cepi founded by Gates himself, has already made agreements for the purchase of vaccines of the multinationals in the orbit of Gates himself from donate to poor populations thanks to contributions from various nations in a clear conflict of interest between speculator and benefactor. It should not be forgotten that the IT guru's foundation has for more than ten years funded the dangerous bacteriological experiments in the Wuhan Institute where the HIV-infected SARS superviruses were nuilt, as some experts believe to be SARS-Cov-2.

*All details in the Gospa News menu item so named.*